![16 9 size People working in a lab](/sites/default/files/hk/en/2022-08/16%209%20size%20People%20working%20in%20a%20lab_0.jpg)
August 03, 2022
First half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline
![CHMP_website_teaser_card_16_](/sites/default/files/hk/en/2022-06/CHMP_website_teaser_card_16_9.jpg)
June 28, 2022
CHMP issues positive opinion to expand Jardiance (empagliflozin) indication based on unprecedented benefit in adult heart failure patients with preserved ejection fraction
![COVID-19研究中的治疗停止 COVID-19研究中的治疗停止](/sites/default/files/hk/en/2022-06/press-release-holding-image01.jpg)
June 23, 2022
Stop of treatment in COVID-19 study
![T cell](/sites/default/files/hk/en/2022-07/T-cell%201440_810.jpeg)
June 14, 2022
Option to Acquire Trutino Biosciences
![humbnail](/sites/default/files/hk/en/2022-07/thumbnail%281%29.jpg)
June 02, 2022
A*STAR antibodies bolster ADC and T-Cell engager development
![BI_PF_ATS_Press-Release_Social BI_PF_ATS_Press-Release_Social](/sites/default/files/hk/en/2022-07/786212706-002_BI_PF_ATS_Press-Release_Social_1920x1080_CC03_image-only_0.jpg)
May 15, 2022
Investigational treatment slowed lung function decline in IPF
![TwistPak TwistPak](/sites/default/files/hk/en/2022-07/TwistPak%20hero%20image.jpg)
May 12, 2022
TwistPak®: Mixing platform for swine vaccines brings convenience and flexibility
![AI machine deep learning](/sites/default/files/hk/en/2022-08/AI%20machine%20deep%20learning.jpg)
May 11, 2022
Boehringer Ingelheim’s signal analytics technology is acquired by ArisGlobal
![048_© 2020, Peter Ginter - final adjustments at the “pipe crossover” resized](/sites/default/files/hk/en/2022-08/048_%C2%A9%202020%2C%20Peter%20Ginter%20-%20final%20adjustments%20at%20the%20%E2%80%9Cpipe%20crossover%E2%80%9D%20resized.jpeg)
April 05, 2022
Good business performance gives Boehringer Ingelheim tailwind for investment in Research and Development
![新的spesolimab数据显示GPP复发显著改善](/sites/default/files/hk/en/2022-06/AAD%20press%20release%20supporting%20image_resized.png)
March 28, 2022
New spesolimab data show significant improvement in GPP flares
![AAD press release](/sites/default/files/hk/en/2022-08/AAD%20press%20release%20supporting%20image_resized.jpeg)
March 28, 2022
New spesolimab data show clinically significant improvement in GPP flares
![勃林格殷格翰和世界Buiatrics协会支持反刍动物健康和福利的杰出研究 勃林格殷格翰和世界Buiatrics协会支持反刍动物健康和福利的杰出研究](/sites/default/files/hk/en/2022-06/_15A3705_0.jpg)
March 22, 2022
Boehringer Ingelheim and the World Association for Buiatrics support outstanding research on ruminant animal health and well-being
![220316_EMPA-KIDNEY_Early-Stop](/sites/default/files/hk/en/2022-08/220316_EMPA-KIDNEY_Early-Stop_0.jpg)
March 16, 2022
Jardiance® (empagliflozin) Phase III EMPA-KIDNEY trial will stop early due to clear positive efficacy in people with chronic kidney disease
![EMA_website_teaser_card_16_9](/sites/default/files/hk/en/2022-06/EMA_website_teaser_card_16_9.jpg)
March 07, 2022
Jardiance® (empagliflozin) becomes the first and only approved treatment in Europe for adults with symptomatic chronic heart failure regardless of ejection fraction
Jardiance® (empagliflozin) becomes the first and only approved treatment in Europe for adults with symptomatic chronic heart failure regardless of ejection fraction
![EMPULSE_Image_2_Doctor_Patient](/sites/default/files/hk/en/2022-06/EMPULSE_Image_2_Doctor_Patient.jpg)
March 01, 2022
Empagliflozin provided a significant clinical benefit in adults stabilized in hospital following acute heart failure in EMPULSE Phase III trial
![FDA_website_teaser_card_16_9](/sites/default/files/hk/en/2022-06/FDA_website_teaser_card_16_9.jpg)
February 25, 2022
US FDA approves Jardiance® (empagliflozin) to treat adults with heart failure regardless of left ventricular ejection fraction
![786212575-009_BI_IPF_FDA Asset_1440X810_CC01-01 786212575-009_BI_IPF_FDA Asset_1440X810_CC01-01](/sites/default/files/hk/en/2022-06/786212575-009_BI_IPF_FDA%20Asset_1440X810_CC01-01.jpg)
February 24, 2022
FDA Grants BI 1015550 Breakthrough Therapy Designation for Idiopathic Pulmonary Fibrosis
![test test](/sites/default/files/hk/en/2022-02/2-5.jpg)
February 16, 2022
Boehringer Ingelheim opens Health Management Centre in China
![black cow black cow](/sites/default/files/hk/en/2022-06/black%20cow%202.jpg)
February 09, 2022
New criteria for the susceptibility testing of Ubrolexin® when treating mastitis in dairy cows
![Mediapool_TopEmployer2022](/sites/default/files/hk/en/2022-08/Mediapool_TopEmployer2022%20%281%29.jpg)
January 20, 2022
Award: Boehringer Ingelheim is Global Top Employer 2022
![Immuno Immuno](/sites/default/files/hk/en/2022-09/400x400smallformat_Immuno.jpg)
January 18, 2022
Collaboration with MabGenesis to discover and develop novel monoclonal antibodies in canine
![勃林格殷格翰和Lifebit宣布合作捕获健康数据的转化价值 勃林格殷格翰和Lifebit宣布合作捕获健康数据的转化价值](/sites/default/files/hk/en/2022-06/400x400smallformat_Digital1.jpg)
January 03, 2022
Boehringer Ingelheim and Lifebit announce partnership to capture transformational value of health data
![EMA验证了spesolimab在GPP中的上市许可申请](/sites/default/files/hk/en/2022-06/press-release-holding-image03_1.jpg)
December 29, 2021
EMA validates spesolimab marketing authorization application in GPP
![Spesolimab II期数据](/sites/default/files/hk/en/2022-06/Supporting%20press%20release%20image.png)
December 23, 2021
Spesolimab Phase II data
![美国FDA授予spesolimab在GPP中的优先审评](/sites/default/files/hk/en/2022-06/211213%20FDA%20Press%20Release%20Image_1440x810_72dpi_cc01.jpg)
December 15, 2021
U.S. FDA grants priority review for spesolimab in GPP
![勃林格殷格翰和Lifebit宣布合作捕获健康数据的转化价值 勃林格殷格翰和Lifebit宣布合作捕获健康数据的转化价值](/sites/default/files/hk/en/2022-06/press-release-holding-image01_0.jpg)
December 10, 2021
Boehringer Ingelheim Launches University of Medicine Excellence
![Boehringer Ingelheim启动Boehringer Ingelheim Social Engagements Boehringer Ingelheim启动Boehringer Ingelheim Social Engagements](/sites/default/files/hk/en/2022-06/BISE_Bungoma_County%5B1%5D.jpg)
November 11, 2021
Boehringer Ingelheim launches Boehringer Ingelheim Social Engagements
![共同创造更多健康2021: 为脆弱社区的5000万人创造可持续的健康解决办法 共同创造更多健康2021: 为脆弱社区的5000万人创造可持续的健康解决办法](/sites/default/files/hk/en/2022-06/MMHT_visual.jpg)
November 11, 2021
Making More Health Together 2021: Creating sustainable health solutions for 50 million people in vulnerable communities
![防腐肾亚组分析 press-release-holding-image02_1.jpg](/sites/default/files/hk/en/2022-06/press-release-holding-image02_1.jpg)
November 06, 2021
Empagliflozin shows consistent cardio-renal benefits in adults with heart failure with left ventricular ejection fraction over 40 percent regardless of chronic kidney disease status
![勃林格殷格翰增加了对可持续发展的承诺, 通过社会创新影响5000万人 勃林格殷格翰增加了对可持续发展的承诺, 通过社会创新影响5000万人](/sites/default/files/hk/en/2022-06/More%2520Potential_Picture%2520for%2520Tweet%5B1%5D.jpg)
November 03, 2021
Boehringer Ingelheim increases commitments to sustainable development, to impact 50 million people through social innovation
![Kachelbild SOL](/sites/default/files/hk/en/2022-06/Kachelbild%20SOL.jpeg)
October 27, 2021
科学与创新
![与伦敦大学国王学院的精神卫生合作](/sites/default/files/hk/en/2022-07/AdobeStock_KCL.jpeg)
October 27, 2021
Mental health collaboration with King’s College London
![尿素循环障碍治疗发展伙伴关系](/sites/default/files/hk/en/2022-07/cardpic.png)
October 26, 2021
Partnership to Develop Urea Cycle Disorders Therapy
![MIR_I_klein MIR_I_klein](/sites/default/files/hk/en/2022-06/MIR_I_klein_0.jpg)
October 25, 2021
Boehringer Ingelheim increases commitments to sustainable development, investing in health innovation and collaborations to expand access and improve healthcare for 50 million people in vulnerable communities by 2030
![Aservo®EquiHaler®荣获2021年Pharmapack奖 Aservo®EquiHaler®荣获2021年Pharmapack奖](/sites/default/files/hk/en/2022-06/EquiHaler_001_2019-08-27_exhale_5790_0.jpg)
October 20, 2021
Aservo® EquiHaler® wins 2021 Pharmapack Award
![囊性纤维化基因治疗迈出下一步](/sites/default/files/hk/en/2022-07/AdobeStock_Woman_OxygenMask.jpeg)
October 19, 2021
Cystic Fibrosis Gene Therapy Takes to Next step
![img](/sites/default/files/hk/en/2022-07/BI%20TMA%20award%202021_3%20%28005%29%20%281%29_0.jpeg)
October 11, 2021
Boehringer Ingelheim awards its first Translational Medicine Award
![勃林格殷格翰将扩大法国新出现和跨界疾病的兽用疫苗接种能力 勃林格殷格翰将扩大法国新出现和跨界疾病的兽用疫苗接种能力](/sites/default/files/hk/en/2022-06/Lyon-Jonage%20.jpg)
October 08, 2021
Boehringer Ingelheim to expand veterinary vaccine capacity for emerging and transboundary diseases in France
![LSCC_Kachelbild](/sites/default/files/hk/en/2022-08/LSCC_Kachelbild.jpg)
October 06, 2021
Boehringer Ingelheim inaugurates biopharmaceutical production facility in Vienna, Austria
![世界狂犬病日:对抗狂犬病错误观念 世界狂犬病日:对抗狂犬病错误观念](/sites/default/files/hk/en/2022-06/WRD%20press%20release%20tile%20image%20option%202.png)
September 28, 2021
World Rabies Day: fighting rabies misconceptions
![Reserach and developmen Reserach and developmen](/sites/default/files/hk/en/2022-06/Reserach%20and%20development.png)
September 27, 2021
Boehringer Ingelheim and Invetx announce strategic collaboration
![2021 European PRRS Research Award winners 2021 European PRRS Research Award winners](/sites/default/files/hk/en/2022-06/2021%20European%20PRRS%20Research%20Award%20winners.png)
September 23, 2021
2021 European PRRS Research Award winners announced
![获得以推进癌症免疫学研究](/sites/default/files/hk/en/2022-07/shutterstock_274014893_0.jpg)
September 21, 2021
Acquisition to advance cancer immunology research
![与安进就KRAS进行临床合作](/sites/default/files/hk/en/2022-07/WebsiteCard.jpg)
September 16, 2021
Clinical collaboration with Amgen on KRAS
![联合使用Ingelvac CircoFLEX®和Ingelvac PRRSFLEX EU®的积极意见 联合使用Ingelvac CircoFLEX®和Ingelvac PRRSFLEX EU®的积极意见](/sites/default/files/hk/en/2022-06/Brazil_IMG_7057_400.jpg)
September 15, 2021
Positive opinion for combined use of Ingelvac CircoFLEX® and Ingelvac PRRSFLEX EU®
September 13, 2021
FRONTLINE® becomes Brand of the Year 2021-2022
![COVID-19研究中的治疗停止 COVID-19研究中的治疗停止](/sites/default/files/hk/en/2022-06/press-release-holding-image01.jpg)
September 09, 2021
Empagliflozin receives Breakthrough Therapy Designation in U.S. for heart failure with preserved ejection fraction (HFpEF)
![勃林格殷格翰和Twist Bioscience进入治疗性抗体发现合作](/sites/default/files/hk/en/2022-07/press-release-holding-image03.jpg)
September 09, 2021
Boehringer Ingelheim and Twist Bioscience Enter Therapeutic Antibody Discovery Collaboration
![勃林格殷格翰宣布美国国家董事总经理Jean-Michel Boers被任命为PhRMA董事会成员](/sites/default/files/hk/en/2022-06/press-release-holding-image01_1.jpg)
August 27, 2021
Landmark trial demonstrates empagliflozin is the first therapy to show statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction
![2021年上半年:勃林格殷格翰公司在研发方面取得了根本性进展 2021年上半年:勃林格殷格翰公司在研发方面取得了根本性进展](/sites/default/files/hk/en/2022-06/Pressebild_Boehringer_Ingelheim.png)
August 03, 2021
First half of 2021: Boehringer Ingelheim makes fundamental progress in research and development
![press-release-holding-image01](/sites/default/files/hk/en/2022-07/press-release-holding-image01.jpg)
July 26, 2021
Boehringer Ingelheim Focuses COVID-19 Clinical Research on Alteplase
![2021年上半年:勃林格殷格翰公司在研发方面取得了根本性进展 2021年上半年:勃林格殷格翰公司在研发方面取得了根本性进展](/sites/default/files/hk/en/2022-06/248400545-2.jpg)
July 16, 2021
Flood disaster in Germany: donation increased to EUR 1 million
![新型FreVAX™智能手机应用将仔猪疫苗接种提高到另一个水平 新型FreVAX™智能手机应用将仔猪疫苗接种提高到另一个水平](/sites/default/files/hk/en/2022-06/DSC_0499_BIPigSoundTalks_KNAPP_04242019.jpg)
July 13, 2021
New FreVAX™ smartphone application brings piglet vaccination to another level
![press-release-holding-image02](/sites/default/files/hk/en/2022-06/press-release-holding-image02_0.jpg)
July 06, 2021
Breakthrough results for empagliflozin confirm EMPEROR-Preserved as first and only successful trial for heart failure with preserved ejection fraction
![勃林格殷格翰庆祝在欧洲对抗PRRS 25年 勃林格殷格翰庆祝在欧洲对抗PRRS 25年](/sites/default/files/hk/en/2022-06/Pigs.jpg)
June 30, 2021
Boehringer Ingelheim celebrates 25 years to combat PRRS in Europe
![2021青年科学家奖获得者宣布 2021青年科学家奖获得者宣布](/sites/default/files/hk/en/2022-06/ABCD%20award%20tile%20image.png)
June 28, 2021
2021 Young Scientist Award winners announced
![T2D治疗中的实际获益-展示 press-release-holding-image01_3.jpg](/sites/default/files/hk/en/2022-06/press-release-holding-image01_3.jpg)
June 28, 2021
Empagliflozin reduced the risk of cardiovascular events and hospitalization for heart failure compared to DPP-4 inhibitors in people with type 2 diabetes
Empagliflozin reduced the risk of cardiovascular events and hospitalization for heart failure compared to DPP-4 inhibitors in people with type 2 diabetes
![心脏衰竭-治疗-批准-欧洲 press-release-holding-image03_Square.jpg](/sites/default/files/hk/en/2022-06/press-release-holding-image03_Square.jpg)
June 21, 2021
Jardiance® (empagliflozin) approved in Europe for the treatment of heart failure with reduced ejection fraction
![合作 用Lifebit检测全球传染病暴发 合作 用Lifebit检测全球传染病暴发](/sites/default/files/hk/en/2022-06/Data.jpg)
June 09, 2021
Partnering with Lifebit to detect global infectious disease outbreaks
Partnering with Lifebit to detect global infectious disease outbreaks
![BI_1122_0](/sites/default/files/hk/en/2022-07/BI_1122_0.jpg)
June 02, 2021
NASH Treatment Receives FDA Fast Track Designation
![press-release-holding-image02](/sites/default/files/hk/en/2022-06/press-release-holding-image02.jpg)
May 25, 2021
FDA Breakthrough Therapy Designation for investigational treatment in cognitive impairment associated with Schizophrenia
![press-release-holding-image01](/sites/default/files/hk/en/2022-06/press-release-holding-image01_2.jpg)
May 21, 2021
Positive CHMP opinion for a heart failure indication
![Horse9 Horse9](/sites/default/files/hk/en/2022-06/Horse9.jpg)
May 18, 2021
Boehringer Ingelheim officially starts equine business in China
![Card_image_Yale](/sites/default/files/hk/en/2022-07/Card_image_Yale.jpg)
May 10, 2021
Biomedical Data Science Fellowship Program with Yale
![cattle herd cattle herd](/sites/default/files/hk/en/2022-06/cattle%20herd.jpg)
April 15, 2021
Boehringer Ingelheim adds blue internal teat sealant to its portfolio
![MDACC_WebsiteCard](/sites/default/files/hk/en/2022-07/MDACC_WebsiteCard.jpg)
April 14, 2021
Expansion of Collaboration with MD Anderson to Explore KRAS and TRAILR2 Compounds in Lung Cancer
![Germany_Winter Germany_Winter](/sites/default/files/hk/en/2022-06/Germany_Winter%252520%281%29%5B1%5D.jpg)
April 13, 2021
The next generation of Marek’s disease vaccines now available in the EU and the UK
![与安进就KRAS进行临床合作](/sites/default/files/hk/en/2022-07/WebsiteCard.jpg)
April 13, 2021
Phase 2 Clinical Testing in NASH and Obesity
![与LIBD合作,开发集中作用的COMT抑制剂](/sites/default/files/hk/en/2022-07/Lieber_WebsiteCard.jpg)
March 16, 2021
Collaboration with the LIBD to Develop Centrally Acting COMT Inhibitors
![Boehringer Ingelheim和Gubra Join Forces鉴定和 验证治疗肥胖的创新肽 Boehringer Ingelheim和Gubra Join Forces鉴定和 验证治疗肥胖的创新肽](/sites/default/files/hk/en/2022-07/gubra.jpg)
March 01, 2021
Boehringer Ingelheim and Gubra Join Forces to Identify and Validate Innovative Peptides for the Treatment of Obesity
![ATM索引:排名进展&关注早期研发 ATM索引:排名进展&关注早期研发](/sites/default/files/hk/en/2022-06/ATM_Index.jpg)
February 01, 2021
ATM Index: Ranking Progress & Focus on Early-Phase R&D
![奖励:勃林格殷格翰是全球顶级雇主2021 奖励:勃林格殷格翰是全球顶级雇主2021](/sites/default/files/hk/en/2022-06/Top_Employer_2021_Kachel.jpg)
January 25, 2021
Award: Boehringer Ingelheim is Global Top Employer 2021
![Bedroom_Family_Kitten Bedroom_Family_Kitten](/sites/default/files/hk/en/2022-06/Bedroom_Family_Kitten_1135.jpg)
January 13, 2021
EMA marketing authorization for NexGard® COMBO for cats
![thumbnail](/sites/default/files/hk/en/2022-07/thumbnail.jpg)
January 12, 2021
Collaboration with Enara Bio on Cancer Immunotherapies
![量子计算:勃林格殷格翰和谷歌制药研发合作伙伴 量子计算:勃林格殷格翰和谷歌制药研发合作伙伴](/sites/default/files/hk/en/2022-06/2019_SB_Google_0262.jpg)
January 11, 2021
Quantum Computing: Boehringer Ingelheim and Google Partner for Pharma R&D
![勃林格殷格翰股份更新2030环境可持续性承诺 勃林格殷格翰股份更新2030环境可持续性承诺](/sites/default/files/hk/en/2022-06/MoreGreenCard_400x400px.png)
January 11, 2021
Boehringer Ingelheim shares updated 2030 environmental sustainability commitments
![接种疫苗 与Enterisol®Ileitis联用可减少猪中的沙门氏菌 接种疫苗 与Enterisol®Ileitis联用可减少猪中的沙门氏菌](/sites/default/files/hk/en/2022-06/GettyImages-504193372_M.jpg)
January 07, 2021
Vaccinating with Enterisol® Ileitis reduces Salmonella in swine
![SARS-CoV-2中和抗体进入临床阶段 SARS-CoV-2中和抗体进入临床阶段](/sites/default/files/hk/en/2022-06/NewAntibodies.jpg)
December 18, 2020
SARS-CoV-2 Neutralizing Antibody enters Clinical Phase
![humbnail](/sites/default/files/hk/en/2022-07/thumbnail%281%29.jpg)
December 10, 2020
Boehringer Ingelheim to acquire NBE-Therapeutics
![LINDEN_Website_Card](/sites/default/files/hk/en/2022-07/LINDEN_Website_Card.jpg)
December 09, 2020
Boehringer Ingelheim to acquire Labor Dr. Merk & Kollegen
![Proxygen_Website](/sites/default/files/hk/en/2022-07/Proxygen_Website.jpg)
December 07, 2020
Collaboration with Proxygen on Molecular Glue Degraders
![勃林格殷格翰:数字实验室BI X促进全球伙伴关系 勃林格殷格翰:数字实验室BI X促进全球伙伴关系](/sites/default/files/hk/en/2022-06/Datacenter_09_0.jpg)
December 01, 2020
Boehringer Ingelheim: Digital Lab BI X Facilitates Global Partnerships
![勃林格殷格翰宣布美国国家董事总经理Jean-Michel Boers被任命为PhRMA董事会成员](/sites/default/files/hk/en/2022-06/press-release-holding-image01_1.jpg)
November 16, 2020
Boehringer Ingelheim receives positive CHMP opinion for use of Pradaxa® (dabigatran etexilate) for the treatment and prevention of venous thromboembolic events in children from birth to less than 18 years of age
![press-release-holding-image01](/sites/default/files/hk/en/2022-06/press-release-holding-image01_2.jpg)
November 05, 2020
New Analysis Supports Long-Term Treatment with nintedanib in SSc-ILD Patients1
![开发重度COVID19并发症的潜在治疗方法 开发重度COVID19并发症的潜在治疗方法](/sites/default/files/hk/en/2022-06/COVID19.jpeg)
October 28, 2020
Developing potential treatment for severe COVID19 complications
![与OBT的扩大联盟推进了癌症免疫学管线](/sites/default/files/hk/en/2022-07/shutterstock_1038911209.jpg)
October 14, 2020
Expanded alliance with OBT advances cancer immunology pipeline
![AdobeStock_ResearchersWithFaceMasks2](/sites/default/files/hk/en/2022-07/AdobeStock_ResearchersWithFaceMasks2.jpg)
September 17, 2020
Boehringer Ingelheim and Mirati Therapeutics Announce Clinical Collaboration to Study BI 1701963, a SOS1::pan-KRAS Inhibitor in Combination with MRTX849, a KRAS G12C Selective Inhibitor
![识别成功的IT转换:勃林格殷格翰获得2020年数字领袖奖 识别成功的IT转换:勃林格殷格翰获得2020年数字领袖奖](/sites/default/files/hk/en/2022-06/400_Datacenter_05.jpg)
September 16, 2020
Successful IT transformation recognized: Boehringer Ingelheim wins Digital Leader Award 2020
![press-release-holding-image01](/sites/default/files/hk/en/2022-06/press-release-holding-image01_2.jpg)
September 14, 2020
Phase II trial results demonstrated improvement in cognition with BI 425809 in adult patients with schizophrenia
![Boehringer Ingelheim and Click Therapeutics Enter into Collaboration to Develop and Commercialize CT-155, a Novel Prescription Digital Therapeutic to Aid in the Treatment of Schizophrenia Boehringer Ingelheim and Click Therapeutics Enter into Collaboration to Develop and Commercialize CT-155, a Novel Prescription Digital Therapeutic to Aid in the Treatment of Schizophrenia](/sites/default/files/hk/en/2022-07/BI%20CARMEN%20Press%20Release%20klein.jpg)
September 11, 2020
Boehringer Ingelheim and Click Therapeutics Enter into Collaboration to Develop and Commercialize CT-155, a Novel Prescription Digital Therapeutic to Aid in the Treatment of Schizophrenia
Boehringer Ingelheim and Click Therapeutics Enter into Collaboration to Develop and Commercialize CT-155, a Novel Prescription Digital Therapeutic to Aid in the Treatment of Schizophrenia
![勃林格殷格翰停止开发BI 1467335治疗糖尿病性视网膜病](/sites/default/files/hk/en/2022-07/press-release-holding-image03%20%281%29.jpg)
September 07, 2020
Boehringer Ingelheim discontinues development of BI 1467335 for Diabetic Retinopathy
![press-release-holding-image03](/sites/default/files/hk/en/2022-06/press-release-holding-image03.jpg)
September 02, 2020
Final analysis of the observational GioTag study: Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer
![勃林格殷格翰宣布美国国家董事总经理Jean-Michel Boers被任命为PhRMA董事会成员](/sites/default/files/hk/en/2022-06/press-release-holding-image01_1.jpg)
August 27, 2020
Boehringer Ingelheim Announces U.S. Country Managing Director Jean-Michel Boers Appointed to PhRMA Board of Directors
![欧洲最大的倡议启动加速COVID-19和未来冠状病毒威胁的治疗开发 欧洲最大的倡议启动加速COVID-19和未来冠状病毒威胁的治疗开发](/sites/default/files/hk/en/2022-06/CoronavirusCollage.jpeg)
August 18, 2020
Europe’s Largest Initiative Launches to Accelerate Therapy Development for COVID-19 and Future Coronavirus Threats
![press-release-holding-image01](/sites/default/files/hk/en/2022-06/press-release-holding-image01_2.jpg)
August 12, 2020
Phase III InPedILD™ trial enrolls first patient to evaluate nintedanib in pediatric population with fibrosing interstitial lung disease
![2020年上半年:对抗COVID-19大流行塑造了勃林格殷格翰的全球业务活动 2020年上半年:对抗COVID-19大流行塑造了勃林格殷格翰的全球业务活动](/sites/default/files/hk/en/2022-06/Kachel%20Website_Halbjahres.jpg)
August 03, 2020
First half 2020: Fight against COVID-19 pandemic shapes global business activities of Boehringer Ingelheim
![press-release-holding-image01](/sites/default/files/hk/en/2022-06/press-release-holding-image01_2.jpg)
July 30, 2020
Empagliflozin meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in Phase III trial in adults with and without diabetes
![press-release-holding-image01](/sites/default/files/hk/en/2022-06/press-release-holding-image01_2.jpg)
July 15, 2020
European Commission approves third nintedanib indication in pulmonary fibrosis1
![全球调查显示,COPD年轻患者的疾病感知负担更大 全球调查显示,COPD年轻患者的疾病感知负担更大](/sites/default/files/hk/en/2022-06/press-release-holding-image03_0.jpg)
July 09, 2020
Perceived burden of disease is greater in younger people living with COPD, global survey reveals
![抗击抗生素耐药性:勃林格殷格翰加入AMR行动基金 抗击抗生素耐药性:勃林格殷格翰加入AMR行动基金](/sites/default/files/hk/en/2022-06/R%26D_014.jpg)
July 09, 2020
Fighting antibiotic resistance: Boehringer Ingelheim joins AMR Action Fund
![NewAntibodies_0](/sites/default/files/hk/en/2022-07/NewAntibodies_0.jpeg)
July 07, 2020
Numab Therapeutics and Boehringer Ingelheim Enter into Collaboration to Develop Multi-specific Antibody Therapeutics for Cancer and Retinal Diseases
![EUbOPEN_PM_Website](/sites/default/files/hk/en/2022-07/EUbOPEN_PM_Website.jpg)
June 08, 2020
New consortium EUbOPEN will provide tools to unlock disease biology
![NewAntibodies_0](/sites/default/files/hk/en/2022-07/NewAntibodies_0.jpeg)
June 07, 2020
Boehringer Ingelheim Acquires Northern Biologics’ Preclinical Cancer Antibody Pipeline, Expanding Immuno-oncology Portfolio
![LastMile LastMile](/sites/default/files/hk/en/2022-06/LastMile%20%282%29.png)
June 04, 2020
“LastMile”——通过数字化改进
![press-release-holding-image02](/sites/default/files/hk/en/2022-06/press-release-holding-image02_0.jpg)
May 29, 2020
Boehringer Ingelheim receives positive CHMP opinion for a third nintedanib indication in pulmonary fibrosis1
![Candlelight.](/sites/default/files/hk/en/2022-07/Candlelight.jpg)
May 13, 2020
Boehringer Ingelheim Collaborates with CDR-Life to Develop Antibody Fragment-based Therapeutics for Geographic Atrophy, a Leading Cause of Blindness Worldwide
![全球调查显示,COPD年轻患者的疾病感知负担更大 全球调查显示,COPD年轻患者的疾病感知负担更大](/sites/default/files/hk/en/2022-06/press-release-holding-image03_0.jpg)
April 21, 2020
European Commission approves nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD)
![勃林格殷格翰将患者需求置于最新“PatientView”调查结果的首位 勃林格殷格翰将患者需求置于最新“PatientView”调查结果的首位](/sites/default/files/hk/en/2022-06/Patienten-organsations%20Fotolia_137152796_X%20%281%29.jpg)
April 21, 2020
Boehringer Ingelheim puts patient needs first as reflected in the results of the latest “PatientView” survey
![manufacturing_facility](/sites/default/files/hk/en/2022-07/biopharmaceutical_manufacturing_facility_Shanghai%2C600x450px_0.jpg)
April 09, 2020
Boehringer Ingelheim Biopharmaceuticals China receives “Facility of the Year” Award
![Fluid-Bed-Coater_IMG_8814 Fluid-Bed-Coater_IMG_8814](/sites/default/files/hk/en/2022-06/Fluid-Bed-Coater_IMG_8814.jpg)
April 08, 2020